TY  - CHAP
M1  - Book, Section
TI  - Heart Failure
A1  - Bashore, Thomas M.
A1  - Granger, Christopher B.
A1  - Jackson, Kevin P.
A1  - Patel, Manesh R.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Key  Clinical  Updates  in  Heart  FailureTwo  large  clinical  trials  of  patients  with  type  2  diabetes  have  shown  that  inhibitors  of  SGLT2  substantially  reduce  the  risk  of  cardiovascular  death  and  hospitalization  for  heart  failure  for  patients  with  reduced  EF,  with  or  without  diabetes.Dapagliflozin  also  reduced  all-cause  mortality  and  has  been  approved  for  treating  heart  failure  with  reduced  EF.  Empagliflozin  is  under  FDA  review.While  SGLT2  inhibitors  also  reduced  renal  disease  progression,  patients  with  severe  renal  impairment  were  not  included  in  these  trials.In  2021,  the  FDA  approved  vericiguat  to  reduce  the  risk  of  cardiovascular  death  and  heart  failure  hospitalization  following  hospitalization  for  heart  failure  in  patients  with  chronic  heart  failure  and  EF  <  45%.The  VICTORIA  trial  showed  a  modest  but  significant  reduction  in  cardiovascular  death  and  heart  failure  hospitalization  with  vericiguat,  on  top  of  other  effective  therapies,  in  this  high-risk  population.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184696261
ER  -